CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status

We investigated CD49d (also termed ITGA4) expression and its biological and clinical correlations in 415 patients with chronic lymphocytic leukaemia. CD49d expression was stable over the course of the disease. A high expression of CD49d (>30%) was found in 142/415 (34%) patients and was associated with progressive disease (advanced clinical stage, high serum lactate dehydrogenase or β2‐microglobulin levels; all p < 0·05) and aggressive disease biology (increased ZAP70 or CD38, unmutated IGHV, trisomy 12, mutations of NOTCH1 and SF3B1; all P < 0·05). A higher CD49d expression was also associated with a lower blood lymphocyte count and a higher number of lymphoid areas involved by the disease. Patients with high CD49d expression were treated more frequently (55% vs. 27%; P < 0·001) and earlier (median time to treatment [TTT] 65·4 months vs. not reached; P < 0·001) than those with low CD49d expression. However, no significant differences in response rates were observed. In the subgroup of patients with mutated IGHV, high CD49d expression was predictive of a shorter TTT while other markers, such as ZAP70 and CD38, were not. In conclusion, in this study CD49d expression correlated with high‐risk CLL biomarkers and proved to be useful for separating patients with mutated IGHV into two different prognostic groups.

[1]  Jeffrey A Jones,et al.  OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. , 2015, Blood.

[2]  C. Fegan,et al.  Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition , 2014, Leukemia.

[3]  T. Therneau,et al.  An Introduction to Recursive Partitioning Using the RPART Routines , 2015 .

[4]  E. Montserrat,et al.  Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model , 2014, Haematologica.

[5]  A. López-Guillermo,et al.  Survival analysis in hematologic malignancies: recommendations for clinicians , 2014, Haematologica.

[6]  G. Gaidano,et al.  Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. , 2014, Seminars in hematology.

[7]  J. Gribben,et al.  Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. , 2014, Blood.

[8]  C. Fegan,et al.  Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. , 2014, Blood.

[9]  T. Shanafelt,et al.  CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Stephan Stilgenbauer,et al.  Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Shanafelt,et al.  CD 49 d Is the Strongest Flow Cytometry – Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia , 2014 .

[12]  D. Rossi,et al.  CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. , 2013, Blood.

[13]  E. Campo,et al.  A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia , 2012, British journal of haematology.

[14]  D. Rossi,et al.  The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells , 2012, Leukemia.

[15]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[16]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[17]  Y. Calle,et al.  Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP‐9 , 2011, British journal of haematology.

[18]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[19]  D. Rossi,et al.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. , 2009, Cancer research.

[20]  D. Rossi,et al.  CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia , 2008, Haematologica.

[21]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[22]  T. Shanafelt,et al.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential , 2008, British journal of haematology.

[23]  F. Buccisano,et al.  Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. , 2008, Blood.

[24]  F. Buccisano,et al.  Relevance of CD 49 d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia , 2007 .

[25]  K. Stamatopoulos,et al.  ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia , 2007, Leukemia.

[26]  K. Hornik,et al.  Unbiased Recursive Partitioning: A Conditional Inference Framework , 2006 .

[27]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[28]  Christina Gloeckner,et al.  Modern Applied Statistics With S , 2003 .

[29]  Torsten Hothorn,et al.  On the Exact Distribution of Maximally Selected Rank Statistics , 2002, Comput. Stat. Data Anal..

[30]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[31]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[32]  M. Bayık,et al.  Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages. , 1996, Leukemia.

[33]  E. Montserrat,et al.  5th International Workshop on Chronic Lymphocytic Leukemia. , 1992, Leukemia research.